---
title: Cancer Multiomics Resistance Biomarker Question Chain
tags:
  - analysis
  - question-run
  - cancer-multiomics
  - treatment-resistance
  - proteomics
  - phosphoproteomics
themes:
  - llm-wiki-question-chain
  - resistance-biomarkers
  - primary-resistance
  - acquired-resistance
  - functional-state
date: 2026-05-27
---

# Cancer Multiomics Resistance Biomarker Question Chain

This page records a durable LLM-Wiki question chain for the advanced genetics presentation: ask a question, reopen local wiki nodes, expand the wiki, and push the result toward public HTML.

## Key Points

- This is not a paper summary. It is a saved reasoning trail showing how one broad interest, proteome/phosphoproteome-based anticancer resistance biomarkers, becomes a sharper set of research gaps.
- The main outcome is a question ladder, not a single final answer.
- The run preserves the distinction between a **data-design question** ("do we need pre/post?") and the larger **biological biomarker question** ("what kind of resistance state does this signal represent?").
- Scientific content here is grounded in existing local wiki source/analysis pages, not web search.

## Starting Prompt

> I want to use the Cancer Multiomics LLM-Wiki to develop a research question around proteome/phosphoproteome-based anticancer resistance biomarker discovery. I should not simply say "stack evidence layers." I need to find the research gap by asking many questions, expanding the wiki, and letting the questions become sharper.

## Pages Reopened

- [Cancer Multiomics Proteogenomic Atlas](../topics/cancer-multiomics-literature.md)
- [Cancer Multiomics Corpus Queue](./cancer-multiomics-corpus-queue.md)
- [Primary and Acquired Resistance Proteogenomics Ingest Map](./primary-acquired-resistance-proteogenomics-ingest-map.md)
- [Drug Response Proof-of-Concept with Global Proteome, Phosphoproteome, and Somatic SNV](./drug-response-poc-global-phospho-somatic-snv.md)
- [PTM Correction and Kinase Signaling in Cancer Proteomics](../topics/ptm-correction-and-kinase-signaling-in-cancer-proteomics.md)
- [Cancer Multiomics Presentation Storyline](./cancer-multiomics-presentation-storyline.md)

## Question Ladder

### Q1. Can proteome/phosphoproteome data discover anticancer resistance biomarkers?

Initial answer:

- Yes, but this question is too broad.
- The wiki corpus contains multiple response-labeled proteogenomic papers where protein abundance, pathway scores, phosphosite signals, or kinase activity are associated with non-response or resistant states.

Wiki expansion:

- The question was routed to the Cancer Multiomics corpus and drug-response proteogenomics pages rather than treated as a free-form answer.

Gap exposed:

- "Resistance biomarker" can mean several different things: baseline non-response, therapy-emergent acquired resistance, adaptive drug tolerance, or post-treatment refractory state.

Next question:

> What kind of resistance timing or state is each paper actually able to support?

### Q2. What kind of resistance timing does each paper support?

Answer from wiki:

- **Primary resistance**: pre-treatment molecular data plus a response label.
- **Acquired resistance**: same-patient pre/post, progression biopsy, or serial data after treatment pressure.
- **Static refractory state**: treatment-failed sample that describes the current resistant state but cannot prove emergence.
- **Baseline atlas**: treatment-naive feature design resource, useful for choosing readouts but not a direct resistance proof.

Wiki expansion:

- The [Primary and Acquired Resistance Proteogenomics Ingest Map](./primary-acquired-resistance-proteogenomics-ingest-map.md) became the central classification node.
- The presentation storyline was updated to stop treating "pre/post data structure" as the main question; it is now a method question inside a broader biomarker evidence boundary mapping.

Gap exposed:

- The current wiki is stronger for primary resistance and feature-design logic than for same-patient patient-level acquired-resistance proteome/phosphoproteome evidence.

Next question:

> If timing is the first filter, what do proteome and phosphoproteome each add after the timing question is bounded?

### Q3. Do proteome and phosphoproteome describe the same resistance biology?

Answer from wiki:

- No. Protein abundance can mark target abundance, pathway abundance, subtype programs, immune/stromal mixture, or residual cell-state programs.
- Phosphoproteome can mark kinase activity, bypass signaling, target engagement, adaptive signaling, or pathway rewiring.
- A protein marker and a phosphosite/kinase marker may both associate with resistance, but they do not necessarily describe the same biological state.

Wiki expansion:

- The presentation storyline now separates protein abundance markers from phosphosite/kinase state markers.
- The PTM/kinase topic remains connected as a later interpretive layer: if a phosphosite marker is used, the wiki must ask whether it is raw site abundance, protein-corrected site signal, or inferred kinase activity.

Gap exposed:

- Many response papers report phosphoproteomic signals, but the interpretation often needs extra qualification: site-level change, kinase activity, protein-corrected PTM signal, or treatment-adaptive signaling state.

Next question:

> When can a phosphosite or kinase activity signal be called a resistance biomarker rather than just a correlated phosphoproteomic feature?

### Q4. What would make a phosphoproteomic resistance biomarker interpretation strong?

Evidence criteria produced by the wiki:

1. Clear timing: baseline, on-treatment, progression, or refractory.
2. Clear endpoint: pCR/non-pCR, RECIST response, progression, relapse, drug-tolerant state, or refractory status.
3. Clear molecular unit: protein abundance, raw phosphosite, protein-corrected phosphosite, kinase activity score, or pathway score.
4. Clear direction: higher/lower in resistant state, gained after treatment, lost after treatment, or persistent through treatment.
5. Clear validation tier: same cohort only, independent cohort, model system, perturbation, organoid/PDX, IHC/PRM, or clinical association.

Gap exposed:

- A major review gap is not simply the absence of more omics. It is the absence of a shared vocabulary for describing protein/phosphosite resistance biomarkers across primary, acquired, adaptive, and refractory contexts.

Next question:

> Can the review organize existing cancer proteogenomics resistance papers by biomarker evidence type instead of only by cancer type or omics layer?

### Q5. What is the emerging research question family?

The wiki run does not force one final question yet. It produces a ranked family:

1. **Evidence-boundary question**: How should protein/phosphosite resistance biomarkers be classified into baseline resistance, therapy-emergent resistance, adaptive tolerance, and refractory-state markers?
2. **Timing-design question**: What sampling designs are required to distinguish primary resistance from acquired resistance?
3. **Functional-readout question**: Which resistance states are better captured by protein abundance versus phosphosite/kinase activity?
4. **Validation-tier question**: What evidence is required to move from correlated feature to actionable resistance biomarker?
5. **Drug-class question**: Are protein/phosphosite resistance axes shared across chemotherapy, TKI, anti-HER2 therapy, and immunotherapy, or are they drug-class specific?

## Current Presentation-Ready Main Question

> **항암제 내성 바이오마커를 단백체·인산화단백체로 찾으려면, 그 신호가 언제 생긴 내성인지와 어떤 기능 상태를 반영하는지를 어떻게 구분해야 하는가?**

This question contains the pre/post issue, but does not reduce the whole presentation to pre/post design.

## Current Review-Ready Question

> **항암제 내성 proteogenomics 연구에서 발견되는 protein/phosphosite marker를 baseline resistance, therapy-emergent resistance, adaptive tolerance, and refractory-state biomarkers로 구분하기 위한 기준은 무엇인가?**

## Wiki Changes Made From This Run

- Added this question-run page as a durable node.
- Updated [Cancer Multiomics Presentation Storyline](./cancer-multiomics-presentation-storyline.md) so the talk shows many questions rather than one prematurely finalized question.
- Linked this run from the Cancer Multiomics topic hub for public navigation.
- Synced `wiki/` into `wiki_html/content/` after edits so the public Quartz content layer reflects the current wiki.

## Next Run

Run 2 has now been filed as [Cancer Multiomics Resistance Biomarker Evidence Boundary Map](./cancer-multiomics-resistance-biomarker-evidence-boundary-map.md). It chooses one concrete sub-question and expands a source-backed table:

> In response-labeled cancer proteogenomics papers, which reported protein/phosphosite markers are baseline non-response markers, and which ones have any evidence of therapy-emergent change?

Candidate source set:

- [Lee 2026 TNBC](../sources/lee-2026-proteogenomic-decoding-chemotherapy-resistance-tnbc.md)
- [Anurag 2022 TNBC](../sources/anurag-2022-proteogenomic-markers-chemotherapy-resistance-response.md)
- [Holt 2025 MIBC](../sources/holt-2025-proteogenomic-characterization-unveils-biomarkers-associated.md)
- [Jaehnig 2025 HER2+ Breast](../sources/jaehnig-2025-proteogenomic-analysis-calgb-40601-alliance.md)
- [Zhang 2023 ccRCC Sunitinib](../analyses/cancer-multiomics-literature/zhang-2023-proteogenomics-clear-cell-renal-response-tyrosine-kinase-inhibitor.md)
- [Hsu 2025 Osimertinib DTP Phosphoproteomics](../sources/hsu-2025-phosphoproteomics-osimertinib-tolerant-persister-cells-reveals.md)

The next durable page should not be another date-stamped run. It should be a validation-strength table if expanded:

> Which candidate markers survive same-cohort, independent-cohort, perturbation, organoid/PDX, IHC/PRM, or patient-longitudinal validation?

## Connections

- [Cancer Multiomics Presentation Storyline](./cancer-multiomics-presentation-storyline.md)
- [Cancer Multiomics Resistance Biomarker Evidence Boundary Map](./cancer-multiomics-resistance-biomarker-evidence-boundary-map.md)
- [Primary and Acquired Resistance Proteogenomics Ingest Map](./primary-acquired-resistance-proteogenomics-ingest-map.md)
- [Cancer Multiomics Proteogenomic Atlas](../topics/cancer-multiomics-literature.md)
- [PTM Correction and Kinase Signaling in Cancer Proteomics](../topics/ptm-correction-and-kinase-signaling-in-cancer-proteomics.md)

## Sources

- Local wiki pages listed under "Pages Reopened".
- Local source pages linked in the candidate source set.
